Thorne HealthTech acquired by L Catterton
L Catterton acquired Thorne HealthTech, a vitamins & supplements brand on Aug 28, 2023. The transaction value is shown as USD 681m. The current comp implies EV / revenue of 3.7x. Public sources confirm the deal; valuation inputs may include estimates where transaction materials do not disclose the full economics.
Transaction summary
- Target
- Thorne HealthTech
- Acquirer
- L Catterton
- Seller
- -
- Announced
- 2023-08-28
- Geography
- -
- Tags
- CPGPersonalized SupplementsSupplementsVitamins & Supplements
- Type
- Acquisition
- Deal type
- Control
- Stake acquired
- -
- First added
- 2026-06-19
- Latest update
- 2026-07-13
Parties at the deal date
Acquirer
L Catterton is one of the world's leading consumer products focused private equity firms. L Catterton has deep expertise in consumer products, having made more than 200 investments since 1989, and being co-owned by LVMH (which owns brands including Louis Vuitton). We are able to provide our portfolio companies with access to substantial in-house and external resources to drive operational improvements and further growth. L Catterton has five current consumer brand investing platforms: a Flagship Buyout fund focused on $50-400m investments in North American and European companies, a North American Growth fund focused on $10-50m investments, a Latin American Fund focused on $40-75m investments, a Western Europe fund focused on EUR 25-75m investments, and an Asia fund focused on $50-150m investments. L Catterton also has a real estate fund that invests as a co-developer in large scale, mixed-use projects anchored by luxury retail. L Catterton was formed in 2016 through the merger of L Capital (the PE arm of LVMH) and Catterton, a US Private Equity firm.
Snapshot preserved for this transaction; current company profiles may differ.
Value and multiples
Price / value
USD 681M
Enterprise Value | USD
Basis: Public source
EV / revenue
3.7x
Period: varies by source
Basis: FundComb estimate
EV / EBITDA
21.2x
EBITDA: normalised / adjusted
Basis: Derived from source data
Basis
- USD 681m enterprise value is treated as publicly disclosed or derived directly from public source data.
- EV / revenue is shown as 3.7x based on the available comp inputs.
- Revenue and multiple inputs are not fully disclosed in public transaction materials reviewed; treat the multiple as an estimate.
- Implied EV / EBITDA is 21.2x, calculated from USD 681m value and USD 32.1m EBITDA.
Other reviewed estimates
Transaction comps can involve reported or estimated figures from different sources. FundComb uses the values above as the current canonical comp, while preserving prior reviewed estimates below for context.
Source summary
Thorne HealthTech Schedule 14D-9/A
EstimatedAmended solicitation/recommendation statement discloses Canaccord precedent transaction analysis and proposed Thorne transaction implied TEV and LTM Adjusted EBITDA multiple.
Open source